ClearPoint Neuro Q4 revenue $6.8M (+32% YoY); FY2023 revenue $24M (+17%); reaffirms 2024 guidance $28M-$32M

ClearPoint Neuro, Inc.

Q4 2023 revenue $6.8M, up 32% YoY; full-year revenue $24.0M, up 17% YoY.
Biologics & drug delivery revenue $13.6M in 2023, +49% YoY; gross margin 57% (down from 66%).
Cash & equivalents $23.1M at Dec 31; Q4 cash burn reduced to $1.2M.
Reaffirmed 2024 revenue guidance $28M-$32M; early 2024 milestones include 6 new hospitals, FDA clearance, ~$15M equity offering.
Operating expenses $36.1M in 2023 (up from $29.9M), driven by higher headcount and share-based compensation.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ClearPoint Neuro, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $6.8 million. Guidance reaffirmed.

Period: the fourth quarter ended December 31, 2023
Revenue: $6.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Reported fourth quarter 2023 revenue of $6.8 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ClearPoint Neuro, Inc. reported the fiscal year ended December 31, 2023 results: revenue $24.0 million. Guidance reaffirmed.

Period: the fiscal year ended December 31, 2023
Revenue: $24.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Reported revenue of $24.0 million for the full year 2023

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001285550-24-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.